

What's Next In Vaccines (Malaria, Diabetes, Alzheimer's, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline)

<https://marketpublishers.com/r/H2F084F4C95EN.html>

Date: June 2012

Pages: 215

Price: US\$ 3,995.00 (Single User License)

ID: H2F084F4C95EN

Abstracts

Vaccines are one of the most dynamic parts of the pharmaceutical business today but future growth will depend on a considerable amount of potential vaccines in the pipeline. This Kalorama Information report *What's Next in Vaccines?* examines and estimates the market for vaccines that have yet to be launched. What diseases may see a prophylactics vaccine option in the coming years? Which vaccines will have the most successful business model? Who are the major companies in this market, and possible new entrants? What can current vaccine success stories tell us about the future of the vaccine market? The following target areas are covered in the report:

Acne

Addiction

Allergy

Alzheimer's Disease

Anthrax

Asthma

Campylobacter Infection

Chlamydia

Croup

Cytomegalovirus (CMV)

Dengue Fever

Diabetes

Ebola

Epstein-Barr Virus

Enterotoxigenic Escherichia coli (ETEC)

Heart Attack

Helicobacter Pylori

Hepatitis

Herpesvirus

Hookworm

Hypertension

HIV/AIDS

Leishmaniasis

Malaria

MRSA Infection

Multiple Sclerosis

Obesity

Parainfluenza Virus Type 3

Parkinson's Disease

Plague

Ross River Virus

Shigellosis

Stroke

Tuberculosis

West Nile Virus

For each of these areas the report provides Mortality, Severity and Treatment Availability ratings. For marketers and industry watchers a knowledge of all of the potential vaccines will be important to understand how pharma is seeking to renew bottom line with aggressive prophylactic strategies, and who the winners and losers in the near future may be. Kalorama Information has looked at the vaccine market three times in as many years for Kalorama Information, and in this report applies a knowledge of what companies have done in the past to potential efforts.

There are a number of trends that will impact the industry that market watchers will want to know about, and Kalorama Information has covered these trends; including: New Vaccine Technologies, DNA Vaccination, Recent Project Terminations, Innovative Delivery Systems, Edible Vaccines, Vaccine Patches, Funding Shortfalls. The report also discusses vaccine manufacturing methods and the approval process. In addition, the report focuses on the emerging vaccine activities of the following companies

Affiris

Alk-Abello A/S

Allergy Therapeutics

AstraZeneca

Bavarian Nordic A/S

Baxter Healthcare

Crucell

Cytos Biotechnology

GlaxoSmithKline

Hawaii Biotech

Merck & Co. Inc

Mymetics

Nabi Biopharmaceuticals

Novartis

Opexa Therapeutics

Sanofi Pasteur

This report provides forecasted revenues for products in development out to 2021. The report does not cover indication expansions of *existing* vaccine products, nor does it cover vaccines for which products currently exist and are widely available, but may need improvement. Development of vaccines that incorporate new production methods (such as the migration of chicken eggs to mammal, yeast or other cells) is also excluded. Cancer vaccines are excluded as Kalorama has an entire report on this topic. Sales estimates for each market segment represent global revenues and are expressed in current dollars. Information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts' reports and other sources.

Contents

CHAPTER ONE: EXECUTIVE SUMMARY

Emerging Vaccines

Scope and Methodology

Overview

Emerging Vaccines and Forecasts

The Global Market for Emerging Vaccines

CHAPTER TWO: INTRODUCTION TO VACCINES

A Brief History: The Development of Vaccines

The Immune Response

Mechanism of Action

Types of Vaccines

Attenuated (Weakened) Live Viruses

Killed (Inactivated) Viruses

Toxoid Vaccines

Genetically Engineered/Modified Vaccines

Bacteria-Based Vaccines

Vaccine Approval Process

Refusal to Immunize

Expanding Vaccine Availability

Other Trends Driving the Vaccines Market

CHAPTER THREE: EMERGING VACCINES

Introduction

Emerging Vaccines by Disease Area

Acne

Addiction

Allergy

Alzheimer's Disease

Anthrax

Asthma

Campylobacter Infection

Chlamydia

Croup

Cytomegalovirus (CMV)
Dengue Fever
Diabetes
Ebola
Epstein-Barr Virus
Enterotoxigenic Escherichia coli (ETEC)
Heart Attack
Helicobacter Pylori
Hepatitis
Herpesvirus
Hookworm
Hypertension

HIV/AIDS

Leishmaniasis
Malaria
MRSA Infection
Multiple Sclerosis
Obesity
Parainfluenza Virus Type 3
Parkinson's Disease
Plague
Ross River Virus
Shigellosis
Stroke
Tuberculosis
West Nile Virus

CHAPTER FOUR: EMERGING VACCINES MARKET FORECAST

the Global Market for Emerging Vaccines
Emerging Vaccines Market Segment Forecasts

Acne
Addiction
Allergies
Alzheimer's Disease
Anthrax
Asthma

Campylobacter Infection
Celiac Disease
Chlamydia
Croup
Diabetes
Ebola
EBV Infection
ETEC Infection
Heart Attack
H. Pylori Infection
Hepatitis C and E
Herpesvirus Infection
Hookworm
Hypertension

HIV/AIDS

Leishmaniasis
Malaria
MRSA Infection
Multiple Sclerosis
Obesity
PIV-3 Infection
Parkinson's Disease
Plague
RSV Infection
Ross River Virus Infection
Shigellosis
Stroke
Tuberculosis
West Nile Virus

CHAPTER FIVE: ISSUES AND TRENDS

New Vaccine Delivery System
Edible Vaccines
Mucosal Delivery
Intranasal Delivery
Vaccine Patches

Funding Shortfalls
Project Terminations

CHAPTER SIX: COMPANY PROFILES

Affiris

- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information

Alk-Abello A/S

- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information

Allergy Therapeutics

- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information

AstraZeneca

- History and Lines of Business
- Emerging Vaccine Products
- Financial Information

Bavarian Nordic A/S

- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information

Baxter Healthcare

- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information

Crucell

- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information

Cytos Biotechnology

- History and Lines of Business
- Emerging Vaccine Activities
- Financial

GlaxoSmithKline

- History and Lines of Business

Emerging Vaccine Activities
Financial Information

Hawaii Biotech
History and Lines of Business
Emerging Vaccine Products
Financial Information

Merck & Co. Inc
History and Lines of Business
Emerging Vaccine Activities
Financial Information

Mymetics
History and Lines of Business
Emerging Vaccine Products
Financial Information

Nabi Biopharmaceuticals
History and Lines of Business
Emerging Vaccine Activities
Financial Information

Novartis
History and Lines of Business
Emerging Vaccine Activities
Financial Information

Opexa Therapeutics
History and Lines of Business
Emerging Vaccine Activities
Financial Information

Sanofi Pasteur
History and Lines of Business
Emerging Vaccine Activities
Financial Information

APPENDIX: COMPANY DIRECTORY

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-1: Status of Emerging Vaccines by Disease

CHAPTER TWO: INTRODUCTION TO VACCINES

Table 2-1: Impact of Vaccines in the 20th Century Annual Morbidity in the 20th Century vs 2011

Table 2-2: Vaccine-Preventable Diseases, December 2011

Figure 2-1: Attenuated Virus Production

Table 2-3: VAERS Table of Reportable Events Following Vaccination

CHAPTER THREE: EMERGING VACCINES

Figure 3-1: Global Prevalence of Conditions Addressed by Emerging Vaccines, 2012

Figure 3-2: Comparative Mortality, Symptom Severity and Treatment Availability for Conditions Addressed by Emerging Vaccines

Table 3-1: Emerging Vaccines by Disease and Stage of Testing

Figure 3-3: Comparative Severity Ranking of Acne

Figure 3-4: Comparative Severity Ranking of Addiction

Figure 3-5: Comparative Severity Ranking of Allergy

Figure 3-6: Comparative Severity Ranking of Alzheimer's Disease

Figure 3-7: Comparative Severity Ranking of Anthrax

Figure 3-8: Comparative Severity Ranking of Asthma

Figure 3-9: Comparative Severity Ranking of Campylobacter Infection

Figure 3-10: Comparative Severity Ranking of Celiac Disease

Figure 3-11: Comparative Severity Ranking of Chlamydia

Figure 3-12: Comparative Severity Ranking of Croup

Figure 3-13: Comparative Severity Ranking of Cytomegalovirus

Figure 3-14: Comparative Severity Ranking of Dengue Fever

Figure 3-15: Comparative Severity Ranking of Diabetes

Figure 3-16: Comparative Severity Ranking of Ebola

Figure 3-17: Comparative Severity Ranking of EBV

Figure 3-18: Comparative Severity Ranking of ETEC

Figure 3-19: Comparative Severity Ranking of Heart Attack

Figure 3-20: Comparative Severity Ranking of H. Pylori Infection

Figure 3-21: Comparative Severity Ranking of Hepatitis C and E

Figure 3-22: Comparative Severity Ranking of Herpesvirus Infection

Figure 3-23: Comparative Severity Ranking of Hookworm

Figure 3-24 Comparative Severity Ranking of Hypertension

Figure 3-25: Comparative Severity Ranking of HIV/AIDS

Figure 3-26: Comparative Severity Ranking of Leishmaniasis

Figure 3-27: Comparative Severity Ranking of Malaria

Figure 3-28: Comparative Severity Ranking of MRSA Infection

Figure 3-29: Comparative Severity Ranking of Multiple Sclerosis

- Figure 3-30: Comparative Severity Ranking of Obesity
- Figure 3-31: Comparative Severity Ranking of PIV-3 Infection
- Figure 3-32: Comparative Severity Ranking of Parkinson's Disease
- Figure 3-33: Comparative Severity Ranking of Plague
- Figure 3-34: Comparative Severity Ranking of RSV Infection
- Figure 3-35: Comparative Severity Ranking of Ross River Virus Infection
- Figure 3-36: Comparative Severity Ranking of Shigellosis
- Figure 3-37: Comparative Severity Ranking of Stroke
- Figure 3-38: Comparative Severity Ranking of Tuberculosis
- Figure 3-39: Comparative Severity Ranking of West Nile Virus Infection

CHAPTER FOUR: MARKET ANALYSIS

- Table 4-1: World Market for Emerging Vaccines by Type, 2011
- Table 4-2: World Market for Emerging Vaccines by Type, 2011-2021
- Table 4-3: World Acne Vaccine Market 2011-2021
- Table 4-4: World Addiction Vaccine Market 2011-2021
- Table 4-5: World Allergy Vaccine Market 2011-2021
- Table 4-6: World Alzheimer's Disease Vaccine Market 2011-2021
- Table 4-7: World Anthrax Vaccine Market 2011-2021
- Table 4-8: World Asthma Vaccine Market 2011-2021
- Table 4-9: World Campylobacter Vaccine Market 2011-2021
- Table 4-10: World Celiac Disease Vaccine Market 2011-2021
- Table 4-11: World Chlamydia Vaccine Market 2011-2021
- Table 4-12: World Croup Vaccine Market 2011-2021
- Table 4-13: World Cytomegalovirus Vaccine Market 2011-2021
- Table 4-14: World Dengue Fever Vaccine Market 2011-2021
- Table 4-15: World Diabetes Vaccine Market 2011-2021
- Table 4-16: World Ebola Vaccine Market 2011-2021
- Table 4-17: World EBV Vaccine Market 2011-2021
- Table 4-18: World ETEC Vaccine Market 2011-2021
- Table 4-19: World Heart Attack Vaccine Market 2011-2021
- Table 4-20: World H. Pylori Vaccine Market 2011-2021
- Table 4-21: World Hepatitis C & E Vaccine Market 2011-2021
- Table 4-22: World Herpesvirus Vaccine Market 2011-2021
- Table 4-23: World Hookworm Vaccine Market 2011-2021
- Table 4-24: World Hypertension Vaccine Market 2011-2021
- Table 4-25: World HIV/AIDS Vaccine Market 2011-2021
- Table 4-26: World Leishmaniasis Vaccine Market 2011-2021

- Table 4-27: World Malaria Vaccine Market 2011-2021
- Table 4-28: World MRSA Vaccine Market 2011-2021
- Table 4-29: World Multiple Sclerosis Vaccine Market 2011-2021
- Table 4-30: World Obesity Vaccine Market 2011-2021
- Table 4-31: World PIV-3 Vaccine Market 2011-2021
- Table 4-32: World Parkinson's Disease Vaccine Market 2011-2021
- Table 4-33: World Plague Vaccine Market 2011-2021
- Table 4-34: World RSV Vaccine Market 2011-2021
- Table 4-35: World Ross River Virus Vaccine Market 2011-2021
- Table 4-36: World Shigellosis Vaccine Market 2011-2021
- Table 4-37: World Stroke Vaccine Market 2011-2021
- Table 4-38: World Tuberculosis Vaccine Market 2011-2021
- Table 4-39: World West Nile Virus Vaccine Market 2011-2021

I would like to order

Product name: What's Next In Vaccines (Malaria, Diabetes, Alzheimer's, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline)

Product link: <https://marketpublishers.com/r/H2F084F4C95EN.html>

Price: US\$ 3,995.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H2F084F4C95EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

